Jubilant Pharmova reported its audited consolidated financial results for the financial year ended March 31, 2026. The company recorded total revenue from operations of ₹82,796 million for the year, compared to ₹72,345 million in the previous year. For the quarter ended March 31, 2026, revenue stood at ₹22,900 million, up from ₹19,288 million in the corresponding quarter of the previous year. Following the results announcement, the company has uploaded the audio recording of its earnings webinar held on May 22, 2026, to its website.

Financial Performance

The company reported a consolidated net profit of ₹3,975 million for the year ended March 31, 2026, a decrease from ₹8,363 million in the prior year. For the quarter ended March 31, 2026, the net profit was ₹1,193 million, compared to ₹1,513 million in the same period last year. EBITDA for the quarter was ₹3,415 million, with an EBITDA margin of 14.92%.

Operational Highlights

Revenue growth was driven by strong performance across all business segments, with CDMO Sterile Injectables delivering particularly robust growth. FY26 EBITDA increased by 8% year-on-year to ₹13,260 million. The Radiopharma segment revenue grew by 10% to ₹11,780 million, while the CDMO Sterile Injectables segment revenue surged by 38% to ₹17,550 million. The Allergy Immunotherapy segment revenue grew by 12% to ₹7,850 million.

The company noted that EBITDA margins were impacted during the year due to the temporary shutdown of its CDMO Sterile Injectables facility in Montreal for remediation following FDA observations. Management anticipates EBITDA margins to strengthen from H2 FY27 onwards post-stabilisation of production at Montreal. The company also completed the sale and transfer of its API business to Jubilant Biosys Limited during the year.

Dividend Declaration

The Board of Directors has recommended a final dividend of 500%, or ₹5 per equity share of face value ₹1 each, for the financial year ended March 31, 2026. The total dividend payout amounts to ₹796 million, subject to approval by shareholders. The company has fixed Friday, July 24, 2026, as the record date for determining eligibility for the dividend payment.

Jubilant Pharmova Limited has submitted newspaper advertisements to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The advertisements were published on April 29, 2026, in Financial Express (English Language – All Editions) and Hindustan & Jansatta (Hindi language), addressing critical shareholder initiatives.

Saksham Niveshak Campaign Details

The company is participating in the second 100 Days Campaign - 'Saksham Niveshak' initiative of the Investor's Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs (MCA). This campaign focuses on assisting shareholders in claiming unpaid or unclaimed dividends and updating their Know Your Client (KYC) and nomination details.

Shareholders with outstanding dividends or requiring KYC updates can contact the Company's Registrar and Share Transfer Agent, M/s Alankit Assignments Limited, at Alankit House, 205-208, Anarkali Complex, Jhandewalan Extension, New Delhi - 110055. The RTA can be reached at rta@alankit.com , while shareholders may also contact the company's Nodal Officer at investors@jubi.com .

Special Transfer Window for Physical Shares

In compliance with SEBI Master Circular No. HO/38/13/(4)2026 MIRSD POD/14298/2026 dated February 06, 2026, the company has announced a special window for physical share transfers. This facility continues the initiative previously advertised on February 27, 2026.

The special window accommodates re-lodgement of transfer deeds originally submitted before April 1, 2019 but were rejected, returned, or remained unattended due to documentation or procedural deficiencies. All securities processed under this window will be issued exclusively in dematerialized form and subject to a mandatory one-year lock-in period during which they cannot be transferred, lien marked, or pledged.

Important Exclusions and Requirements

The transfer facility has specific limitations that shareholders must understand:

• Disputed Cases: Matters involving disputes between transferor and transferee are not eligible and must be resolved through appropriate judicial forums such as Courts or NCLT
• IEPF Securities: Securities already transferred to the Investor Education and Protection Fund (IEPF) are not eligible for processing under this facility
• Documentation: Shareholders must contact Alankit Assignments Limited for guidance on required documentation and submission procedures

KYC Updation and Dematerialization Process

Shareholders holding physical shares are requested to update their KYC details using forms available at the company's investor portal. The required information includes PAN, Demat Account Number, Bank Account Number, Email ID, Mobile Number, and Nominee information.

For dematerialized shareholdings, investors must contact their respective Depository Participant (DP) to complete KYC updates. The company strongly encourages conversion of physical share certificates to dematerialized form for enhanced security and easier processing.

The disclosure was signed by Naresh Kapoor, Company Secretary (Membership No: A11782), and dated April 29, 2026. All information is also available on the company's website at www.jubilantpharmova.com .